BioCryst Pharmaceuticals Balance Sheet
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioCryst Pharmaceuticals financial position
At the end of fiscal 2025, BioCryst Pharmaceuticals reported total assets of $514.2 million, up 4.8% from a year earlier against total liabilities of $633.3 million. Shareholders' equity was negative at -$119.2 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $89.7 million in cash and equivalents against $0 of debt, a net cash position of $89.7 million.
The current ratio (current assets divided by current liabilities) was 2.06, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
BioCryst Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 89.74M | 104.71M | 110.64M | 304.77M | 504.39M | 272.13M | 114.17M | 26.73M | 50.28M | 22.10M |
| Short-Term Investments | 185.01M | 216.14M | 278.34M | 119.54M | 3.21M | 28.24M | 22.05M | 77.74M | 64.11M | 32.55M |
| Receivables | 106.82M | 79.07M | 56.95M | 50.60M | 29.41M | 8.65M | 22.15M | 4.29M | 6.12M | 8.77M |
| Inventory | 5.40M | 8.09M | 28.68M | 27.53M | 15.79M | 7.04M | 0 | 1.65M | — | 500.00K |
| Total Current Assets | 404.35M | 421.97M | 495.97M | 516.50M | 566.14M | 323.80M | 164.34M | 114.35M | 125.39M | 66.99M |
| Property, Plant & Equipment | 8.78M | 7.78M | 7.91M | 8.62M | 8.71M | 7.11M | 7.35M | 9.13M | 9.55M | 9.92M |
| Long-Term Investments | 61.16M | 20.32M | 0 | 18.08M | 6.83M | — | 0 | 22.38M | 41.30M | 8.93M |
| Total Assets | 514.16M | 490.42M | 516.96M | 550.00M | 588.15M | 334.71M | 175.28M | 146.84M | 178.26M | 89.85M |
| Accounts Payable | 15.83M | 11.64M | 20.89M | 14.36M | 27.81M | 18.71M | 13.99M | 7.77M | 6.34M | 4.27M |
| Total Current Liabilities | 196.07M | 160.38M | 149.99M | 105.51M | 103.72M | 105.65M | 92.33M | 69.48M | 74.84M | 54.36M |
| Long-Term Debt | 0 | 314.87M | 303.23M | 231.62M | 136.08M | 119.73M | 0 | 30.00M | 23.00M | 23.00M |
| Total Liabilities | 633.31M | 966.35M | 972.49M | 844.60M | 695.14M | 353.98M | 137.03M | 97.61M | 94.49M | 88.27M |
| Shareholders' Equity | -119.15M | -475.93M | -455.53M | -294.60M | -106.99M | -19.26M | 38.25M | 49.23M | 83.77M | 1.58M |
| Retained Earnings | -1.51B | -1.77B | -1.68B | -1.45B | -1.21B | -1.02B | -840.63M | -731.97M | -631.84M | -566.06M |
| Total Debt | 0 | 314.87M | 303.23M | 231.62M | 136.08M | 119.73M | 0 | 30.00M | 23.00M | 23.00M |
| Net Cash (Debt) | 274.75M | 5.98M | 85.76M | 192.69M | 371.52M | 180.63M | 136.23M | 74.47M | 91.40M | 31.65M |
| Shares Outstanding | 213.06M | 208.54M | 205.77M | 187.91M | 184.35M | 176.88M | 154.08M | 110.06M | 98.41M | 73.78M |
This table shows 10 annual periods of BioCryst Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BCRX's reporting calendar. What is a balance sheet?